RPG Life Sciences is in talks with seven global drug companies, including two domestic firms, to form pacts to enter the US market, reports Business Standard.

The company will file six drug master files with the US Food and Drug Administration (US FDA), seeking permission to market active pharmaceutical ingredients.

The company will market the speciality products in the field of cardiovascular drugs, oncology, nephrology and pain management in the European and the US markets and will soon announce some major alliances.

RPG Life Science already has marketing tie-ups with Israel`s drug major Teva for the EU market and with the US-based Apotex for the Canadian market.

In the domestic market, RPG is planning to strengthen its presence by adding more field force and with line extension of major drugs.

The company has leading brands in the market such as Aldactone, Spiromide and Losate in the area of cardiology and Tricaine and Glytop, an anti-diabetic medicine.

Shares of the company were trading up Rs 1.90, or 1.90%, at Rs 101.95. Total volume of shares traded at the BSE was 1280 (10.59 a.m, Friday).